ClinicalTrials.gg
RecruitingNCT07205718Updated Oct 14, 2026

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

A Phase 1/2 interventional study of TAK-188 in Advanced or Metastatic Solid Tumors, sponsored by Takeda. Recruiting at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Takeda · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Oct 14, 2026Enrollment updatedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
273
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 may help to remove these Tregs. Removing these Tregs may allow more cancer-fighting cells (CD8+ T cells) to attack the tumor and potentially stop tumors from growing.

In this study, researchers want to learn if TAK-188 can help the body's immune system better fight cancer in adults with advanced cancers which have not gotten better with regular treatments. The main aims of this study are to check if TAK-188 is safe in adults with advanced or spreading (metastatic) solid tumors, if participants tolerate the treatment with TAK-188 and to learn if TAK-188 works well in adults with certain advanced cancers after their previous treatments didn't work. Participants may receive TAK-188 for up to 1 year. Their health will be monitored after the treatment has ended for up to another year.

02

Conditions studied

  • Advanced or Metastatic Solid Tumors

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants greater than or equal to (≥)18 years or ≥ the local legal age of majority, as applicable, at the time of signing the form.
  2. (ECOG) performance status of 0 to 1.
  3. Participants must provide samples (core needle or other surgical procedure) collected within 21 days prior to Cycle 1 Day 1 (C1D1) and also on treatment unless procedure is determined to be unsafe following discussion with sponsor. Participants with an archival biopsy specimen collected within 90 days prior to C1D1 of TAK-188 who have not received any other cancer-specific treatment (with the exception of endocrine therapy for a history of breast cancer) at least 14 days prior to the biopsy and throughout the period leading up to C1D1 may use that archival specimen in lieu of a new pretreatment biopsy. Archival biopsy from the same tumor must be provided, if available. On-treatment tumor biopsies will be optional in mainland China, but are highly desired.
  4. Adequate bone marrow, renal, and hepatic functions, as determined by the following laboratory parameters:

    1. (ANC) ≥1500 per microliter (μL), count ≥75,000/μL, and (Hgb) ≥8.0 g/dL without growth factor support for ANC or transfusion support for platelets within 14 days before the first trial treatment dose. Transfusion of packed red blood cells is allowed, post infusion Hgb must be greater than 8.0 g/dL.
    2. Total ≤1.5 times the institutional (ULN). For participants with Gilbert's disease, ≤3 milligrams per deciliter (mg/dL).
    3. Serum (ALT) and aspartate aminotransferase (AST) ≤3.0 × ULN or baseline; or, for participants with liver , ≤5.0 × ULN or baseline with liver metastases.
    4. Albumin ≥3.0 grams per deciliter (g/dL).
    5. Adequate renal function, as determined by both of the following:

    <!-- -->

    1. Calculated CLCR (using the Cockcroft-Gault formula) ≥60 mL/minute, and
    2. Urine protein-creatinine ratio (UPCR) of ≤0.5. (For participants with a UPCR >0.5 to \<1, participant may be considered for enrollment only after discussion with the sponsor medical monitor or its designee).

    f. (LVEF) >50%, as measured by echocardiogram or multiple-gated acquisition scan (MUGA) within 4 weeks before receiving the first dose of TAK-188.

  5. toxic effects of previous therapy have recovered to Grade 1 (per National Cancer Institute [NCI CTCAE] v5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, and/or endocrinopathies with stable endocrine replacement therapy.
  6. Female participants must be:

    1. (natural amenorrhea and not due to other medical reasons) for at least 1 year before the screening visit, or
    2. Surgically sterile, or
    3. If they are of , agree to practice 2 effective methods of at the same time, from the time of signing the informed consent through 180 days after the last dose of TAK-188, or
    4. Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant.
    5. Periodic abstinence (for example, calendar ovulation, symptothermal, postovulation methods), withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.
  7. Male participants, even if surgically sterilized (that is, status postvasectomy), must:

    1. Agree to practice effective barrier contraception (that is, a condom) during the entire trial treatment period and through 180 days after the last dose of TAK-188, or
    2. Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant.
    3. Periodic abstinence (for example, calendar ovulation, symptothermal, postovulation methods), withdrawal, and spermicides only are not acceptable methods of contraception.
  8. Voluntary written consent must be given before performance of any trial-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.
  9. Participants with controlled (HIV) are allowed:

    1. Cluster of differentiation 4 (CD4) cell count greater than 350 cell per cubic millimeters (cell/mm\^3).
    2. Viral load undetectable for at least a year.
  10. The following solid tumor participants will be allowed:

    a. Participants with the following confirmed (cytological diagnosis is adequate) locally advanced or metastatic solid tumors, who have progressed on all standard, curative, or life-prolonging treatments (or are intolerant to all available standard therapies): i. Gastroesophageal (esophageal, gastroesophageal junction, and gastric) adenocarcinoma and squamous cell carcinoma.

    ii. pancreatic ductal adenocarcinoma (PDAC). iii. Nonsquamous and squamous nonsmall cell lung cancer (NSCLC) (participants with actionable genomic alteration [AGAs] are allowed in dose escalation only).

    iv. squamous cell carcinoma of head and neck (SCCHN). v. Colorectal cancer.

  11. Participants with metastatic or advanced solid tumors must have radiographically per (RECIST) Version 1.1. Lesions to be used as measurable disease for the purpose of response assessment must either a) not reside in a field that has been subjected to prior radiotherapy or b) have demonstrated clear evidence of radiographic progression since the completion of prior radiotherapy and before trial enrollment or c) have been radiated at least 6 months before trial enrollment or d) should not be the same lesion selected for mandatory biopsy at screening.
  12. For expansion in NSCLC (post programmed cell death-ligand 1 [] treatment):

    1. Participants with pathologically confirmed (cytological diagnosis is adequate) locally advanced or metastatic NSCLC.
    2. Participants must have tested negative for a known AGA (for example, estimated (EGFR), anaplastic lymphoma kinase (ALK), mesenchymal epithelial transition [MET], c-ros oncogene 1 [ROS1], BRAF).
    3. Must have had disease progression in the advanced or metastatic setting. No more than 1 in advanced or metastatic setting is permitted.
    4. Participants must have received at least 6 weeks of 1 prior anti-PD-(L)1 therapy, and this must have been given during the immediately preceding line of therapy. Anti-PD-(L)1 therapy may have been given in the metastatic or neoadjuvant setting.
    5. Participants are eligible regardless of PD-L1 status but this information must be provided.
    6. NOTE: Prior anti-PD-(L)1 therapy may have been given with or without an anti-cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody and/or chemotherapy (for example, carboplatin and pemetrexed).
  13. For phase 1 backfill and possible expansion, in SCCHN (post PD-(L)1 treatment):

    1. Participants with histologically confirmed (cytological diagnosis is acceptable) metastatic or unresectable, recurrent SCCHN that is considered incurable by local therapies. Participants should have PD-(L)1 monotherapy or in combination with chemotherapy administered in the recurrent or metastatic setting or neo-adjuvant/adjuvant. Anti-PD-(L)1 therapy must have been given during the immediately preceding line of therapy. No more than 1 line of therapy in advanced or metastatic setting is permitted.
    2. Anatomic subsites to be included are oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, and paranasal sinuses (maxillary, ethmoid, sphenoid, and frontal). The exception to this is nasopharyngeal cancer and salivary gland tumors, which will not be included.
    3. Participants with oropharyngeal cancer or tumors arising in the paranasal sinuses (maxillary, ethmoid, sphenoid, and frontal) must agree to provide archival tissue for human papillomavirus (HPV) testing or if known, HPV testing results using CINtec p16 histology assay and a 70% cutoff point must be provided. If HPV status was previously tested using this method, no additional testing is required. Otherwise, if another validated HPV assay was performed, tissue will be required for central confirmation.
    4. Tumors must have a PD-L1 combined Positive Score (CPS) ≥1.
  14. For dose expansion in gastroesophageal adenocarcinoma (GEA) (post PD-(L)1 treatment):

    1. Participants with pathologically confirmed (cytological diagnosis is adequate) locally advanced or metastatic gastroesophageal (esophageal, gastroesophageal junction, and gastric) adenocarcinoma.
    2. Must have had disease progression while on or following 1 prior line of therapy:
    3. Disease progression while on or following at least 6 weeks of 1 prior anti-PD-(L)1 therapy in the recurrent locally advanced or metastatic setting. Prior anti-PD-(L)1 therapy may have been given with or without chemotherapy (for example, mFOLFOX or CAPOX); CAPOX); positive participants must have received trastuzumab. Anti-PD-(L)-1 therapy must have been given during the immediately preceding line of therapy. No more than 1 line of therapy in advanced or metastatic setting is permitted.
    4. Tumors must have a PD-L1 CPS ≥1.
  15. For phase 1b backfill and possible expansion in PDAC:

    1. Participants with pathologically confirmed (cytological diagnosis is adequate) locally advanced or metastatic PDAC.
    2. Must have had disease progression in the advanced or metastatic setting. Participants must have had at least 1, and no more than 2, lines of therapy in the advanced or metastatic setting. This may have included standard of care chemotherapies and may include a RAS inhibitor or a combination of the two.

Exclusion criteria

Exclusion Criteria:

  1. History of any of the following cardiac illnesses within 6 months before first dose of TAK-188:

    1. Congestive heart failure Grade III or IV.
    2. Unstable angina, myocardial infarction.
    3. Persistent hypertension ≥160/100 mm mercury (Hg) despite optimal medical therapy.
    4. Ongoing cardiac arrhythmias of Grade >2 (including atrial flutter/fibrillation or intermittent ventricular tachycardia).
    5. Other ongoing serious cardiac conditions (for example, Grade 3 pericardial effusion or Grade 3 restrictive cardiomyopathy).
    6. Symptomatic cerebrovascular events.
    7. Chronic, stable atrial fibrillation on stable anticoagulation therapy, including low molecular-weight heparin, is allowed.
  2. Baseline prolongation of Fridericia- interval (QTcF) (for example, repeated demonstration of QTc >480 milliseconds, history of congenital long QT syndrome, or torsades de pointes) on a 12-lead during the screening period. If participants are taking medications known to prolong QTc at screening, participants may continue to take these medications as long as their baseline QTcF is \<480 milliseconds. Participants may not start using such medications on or after C1D1.
  3. Oxygen saturation of \<90% of room air at screening.
  4. Participants treated with other chemokine (C-C motif) receptor 8 (CCR8) targeting agents within the past 6 months.
  5. Active diagnosis of lung conditions including:

    1. Pneumonitis.
    2. Interstitial lung disease.
    3. Severe .
    4. Idiopathic pulmonary fibrosis.
    5. Other restrictive lung diseases.
    6. Acute symptomatic pulmonary embolism.
    7. Grade ≥2 pleural effusion not controlled by tap or requiring indwelling catheters.
  6. History of known or unless:

    1. Brain metastases are stable on cranial imaging (that is, ≥4 weeks) following prior surgery, whole-brain radiation OR
    2. Stereotactic radiosurgery and off for brain metastases
    3. Must be without neurologic dysfunction that would confound the evaluation of neurologic and other AEs.
  7. Grade ≥2 fever of malignant origin.
  8. Systemic infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before the first dose of TAK-188 or severe infections on continued treatment.
  9. Participants with diseases which currently require ongoing systemic therapy or have required systemic therapy within the preceding 3 months (for example, traditional disease-modifying antirheumatic drugs, biologics, and so forth). Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to an autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  10. Participants with a diagnosis of an identified congenital or acquired immunodeficiency (for example, common variable immunodeficiency, uncontrolled infections, organ transplantation).
  11. Chronic, active hepatitis (for example, participants with known surface antigen seropositive and/or detectable ). Note:

    1. Participants who have positive hepatitis B core antibody can be enrolled but must have an undetectable serum hepatitis B virus-DNA.
    2. Participants who have positive HCV antibody must have an undetectable HCV-RNA serum level.
  12. Prior or current ascites, as measured by physical examination, that requires regularly scheduled paracentesis for control.
  13. Any pre-existing medical or psychiatric condition or illness, metabolic dysfunction, physical examination finding, or clinical laboratory finding that gives reasonable suspicion of a disease or condition that would contraindicate the use of an drug or that would limit compliance with trial requirements or compromise ability to provide written . Participants with a history of pulmonary embolism on anti-coagulation are permitted unless symptomatic requiring oxygen supplementation.
  14. Recent major surgery where the participant has not fully recovered based on physician assessment.
  15. Recent major bleeding event that has not resolved, and the underlying reason for bleeding has not been corrected.
  16. Participant with concurrent requiring active treatment, with the exception of participants on chronic hormonal therapy.
  17. Treatment with fully human/humanized antineoplastic monoclonal antibodies less than 4 weeks or the time period equal to the dosing interval, whichever is shorter. No is required for prior treatment with anti-PD-(L)1 antibodies.
  18. Treatment with any investigational products or other anticancer therapy (including chemotherapy, targeted agents, and immunotherapy), within 14 days or 5 half-lives, whichever is shorter, before C1D1 of TAK-188.
  19. Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy (with the exception of endocrine therapy for a history of breast cancer). Concurrent use of hormones for noncancer-related conditions is acceptable (except for corticosteroid hormones).
  20. Radiation therapy within 14 days (42 days for radiation to the lungs) and/or systemic treatment with radionuclides within 42 days before C1D1 of TAK-188. Participants with clinically relevant ongoing pulmonary complications from prior radiation therapy are not eligible.
  21. Use of systemic corticosteroids or other therapy, concurrently or within 7 days of C1D1 of TAK-188, with the following exceptions:

    1. Topical, intranasal, inhaled, ocular, intra-articular, and/or other nonsystemic corticosteroids.
    2. Physiological doses of replacement steroid therapy (for example, for adrenal insufficiency).
    3. Single doses of steroids (for example, for imaging premedication) within the 7-day timeframe may be allowed after clarification with sponsor.
  22. Receipt of (for example, tuberculosis Bacillus Calmette-Guerin vaccine, oral polio vaccine, measles, rotavirus, yellow fever) within 28 days of C1D1 of TAK-188. Non-live, approved vaccines are allowed (for example, COVID-19 vaccine).

    a. Note: COVID-19 vaccination should not be given within ±3 days of systemic trial treatments.

  23. Recipients of stem cell transplantation or organ transplantation.
  24. Female participants who are lactating or have a positive serum/urine pregnancy test during the screening period or a positive serum/urine pregnancy test on Day 1 before first dose of TAK-188.

    a. Note: Female participants who are lactating will be eligible if they choose to discontinue breastfeeding before the first dose of TAK-188.

  25. Participant is a trial site employee, a site employee's immediate family member (for example, spouse, parent, child, sibling), or is in a dependent relationship with a site employee who is involved in conduct of this trial or may consent under duress.
  26. Participant is considered to be vulnerable, as defined per local regulations and if exclusion is required by local regulations. Examples are persons under safeguard of justice, persons deprived of liberty by judicial or administrative decision, persons receiving psychiatric care without their consent, persons admitted to a health or social establishment for purposes other than research, persons of full age who are subject to a legal protection measure (guardianship or curatorship), and persons unable to express their consent.
Terms in these criteria, in plain language(41)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
273 participants (estimated)

Study arms

  • Experimental
    Phase 1: TAK-188 Dose Escalation

    Participants will receive escalating doses of TAK-188 with a starting dose of 40 micrograms per kilogram (μg/kg), intravenously (IV) infusion, on Days 1, 8, and 15 \[once weekly (QW)\] or Day 1 only \[once every three weeks (Q3W)\] in each 21-day treatment cycles, respectively, or Days 1 and 15 \[once every 2 weeks (Q2W)\] or Day 1 only \[once every 4 weeks (Q4W)\] in 28-day treatment cycles until recommended dose for expansion (RDE) is determined (for a maximum of 12 months).

    Drug: TAK-188

  • Experimental
    Phase 1b: Backfill Cohort

    Participants with squamous cell carcinoma of head and neck (SCCHN) or pancreatic ductal adenocarcinoma (PDAC) will receive TAK-188 at RDE1 (recommended dose for expansion in Phase 1), IV infusion on Days 1, 8, and 15 (QW) in each 21-day treatment cycle (for a maximum of 12 months).

    Drug: TAK-188

  • Experimental
    Phase 2; Dose Expansion: Cohort A

    Participants with non-squamous non-small cell lung cancer (NSCLC) or PDAC will receive TAK-188 at RDE1, IV infusion on Days 1, 8, and 15 (QW) in each 21-day treatment cycle (for a maximum of 12 months).

    Drug: TAK-188

  • Experimental
    Phase 2; Dose Optimization

    Participants with NSCLC/PDAC/SCCHN will receive TAK-188 at RDE1 or RDE2 or RDE3, (where RDE2 and RDE3 represents additional recommended doses or dose schedules) for a maximum of 12 months.

    Drug: TAK-188

  • Experimental
    Phase 2; Dose Expansion: Cohort B (Optional)

    Participants with gastroesophageal adenocarcinoma (GEA) will receive TAK-188 at RDE1, or RDE2 or RDE3, (where RDE2 and RDE3 represents additional recommended doses or dose schedules) for a maximum of 12 months.

    Drug: TAK-188

Interventions

  • DrugTAK-188

    TAK-188 IV infusion.

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. A TEAE is defined as an AE that occurs after administration of first dose of study drug and through 30 days after last dose of study drug or until start of subsequent antineoplastic therapy.

    Time frame: From the signing of the informed consent form (ICF) through 90 days after the last dose (Up to approximately 16 months)

  2. Phase 1: Number of Participants with TEAEs Based on Severity

    An AE is any untoward medical occurrence in a participant administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. A TEAE is defined as an AE that occurs after administration of first dose of study drug and through 30 days after last dose of study drug or until start of subsequent antineoplastic therapy. Severity for each TEAE will be determined using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.

    Time frame: From the signing of the ICF through 90 days after the last dose (Up to approximately 16 months)

  3. Phase 1: Number of Participants with Dose- limiting Toxicities (DLTs)

    DLTs will be evaluated according to NCI CTCAE, Version 5.0 except cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), will be graded according to American society for transplantation and cellular therapy (ASCST) Consensus Grading for CRS.

    Time frame: Up to Cycle 1 (21 days)

  4. Phase 1: Number of Participants with Treatment-emergent Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event.

    Time frame: From the signing of the ICF through 90 days after the last dose (Up to approximately 16 months)

  5. Phase 1: Number of Participants with Treatment-emergent Adverse Events Leading to Dose Modifications and Treatment Discontinuations

    Time frame: From the signing of the ICF through 90 days after the last dose (Up to approximately 16 months)

  6. Phase 1b Backfill and Phase 2 Dose Expansion and Optimization: Overall Response Rate (ORR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    ORR is defined as the percentage of participants who achieve Complete Response (CR) and Partial Response (PR) (determined by the investigator) during the study according to RECIST Version 1.1. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease by 30% and no new sites of disease. Stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

    Time frame: Up to 24 months

  7. Phase 1b Backfill and Phase 2 Dose Expansion and Optimization: Disease Control Rate (DCR)

    DCR is defined as the percentage of participants who achieve SD or better (CR+PR+SD determined by the investigator) equal to or more than (≥) 6 weeks during the study.

    Time frame: Up to 24 months

  8. Phase 1b Backfill and Phase 2 Dose Expansion and Optimization: Duration of Response (DOR)

    DOR is defined as the time from the date of first documentation of a confirmed partial response (cPR) or better to the date of first documentation of PD or death for responders (cPR or better).

    Time frame: Up to 24 months

Secondary outcomes

  1. Phase 1: Recommended Dose for Expansion [RDE(s)] of TAK-188

    RDE will be based on the totality of safety, preliminary efficacy, pharmacokinetic (PK), and pharmacodynamic data from phase 1 dose escalation.

    Time frame: Up to 12 months

  2. Phases 1 and 2: Cmax: Maximum Observed Plasma Concentration for TAK-188

    Time frame: Up to end of treatment (approximately 13 months)

  3. Phases 1 and 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-188

    Time frame: Up to end of treatment (approximately 13 months)

  4. Phases 1 and 2: AUC0-last: Area Under The Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration

    Time frame: Up to end of treatment (approximately 13 months)

  5. Phases 1 and 2: AUC0-inf: Area Under The Plasma Concentration-Time Curve From Time 0 to Infinity

    Time frame: Up to end of treatment (approximately 13 months)

  6. Phases 1 and 2: t1/2z: Terminal Disposition Phase Half-life for TAK-188

    Time frame: Up to end of treatment (approximately 13 months)

  7. Phases 1 and 2: CL: Total Clearance After Intravenous Administration for TAK-188

    Time frame: Up to end of treatment (approximately 13 months)

  8. Phases 1 and 2: Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-188

    Time frame: Up to end of treatment (approximately 13 months)

  9. Phase 1: ORR

    ORR is defined as the percentage of participants who achieve CR and PR (determined by the investigator) during the study according to RECIST Version 1.1. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease by 30% and no new sites of disease. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

    Time frame: Up to 24 months

  10. Phase 1: Disease Control Rate (DCR)

    DCR is defined as the percentage of participants who achieve SD or better (CR+PR+SD determined by the investigator) ≥6 weeks during the study.

    Time frame: Up to 24 months

  11. Phase 1: Duration of Response (DOR)

    DOR is defined as the time from the date of first documentation of a cPR or better to the date of first documentation of PD or death for responders (cPR or better).

    Time frame: Up to 24 months

  12. Phase 1: Time to Response (TTR)

    TTR is defined as the time from the date of first dose administration to the date of first documented cPR or better as determined by the investigator.

    Time frame: Up to 24 months

  13. Phases 1 and 2: Change from Baseline in Regulatory T Cell (Treg) Abundance Within the Tumor Microenvironment (TME)

    Depletion of Treg will be determined using immunohistochemistry assessment in pretreatment and on-treatment tumor biopsy samples.

    Time frame: Baseline, Cycle 2 Day 10 (Cycle length: 21 Days)

  14. Phases 1 and 2: Change from Baseline in Effector T Cell (Teff) Abundance Within the TME

    Increase in Teff \[measured as cytotoxic T cell (CD8+ T cells)\] within the TME will be evaluated using immunohistochemistry assessment in pretreatment and on-treatment tumor biopsy samples.

    Time frame: Baseline, Cycle 2 Day 10 (Cycle length: 21 Days)

  15. Phases 1 and 2: Percentage of Participants Who Develop Anti-TAK-188 Antibodies

    Time frame: Up to the end of treatment (approximately 13 months)

  16. Phase 1b Backfill and Phase 2 Dose Expansion and Optimization: Time to Response (TTR)

    TTR is defined as the time from the date of first dose administration to the date of first documented cPR or better as determined by the investigator.

    Time frame: Up to 24 months

  17. Phase 1b Backfill and Phase 2 Dose Expansion and Optimization: Progression-free Survival (PFS)

    PFS is defined as the time from date of study treatment to the first documented PD based on RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to 24 months

  18. Phase 1b Backfill and Phase 2 Dose Expansion and Optimization: Overall Survival (OS)

    OS is defined as the time from the date of first dose administration to the date of death, in all participants who received treatment on Cycle 1 Day 1 (C1D1).

    Time frame: Up to 24 months

07

Study locations

15 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Dec 2028, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Oct 3, 2025
StartActual
Nov 19, 2025
Primary completionEst.
Dec 26, 2028
CompletionEst.
Dec 21, 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
223→273
Oct 14, 2026
Eligibility
9 inclusion criteria edited, 6 added; 4 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedParticipants greater than or equal to (≥)18 years or ≥ the local legal age of majority, as applicable, at the time of signing the ICFinformed consent form.
  • EditedParticipants must provide biopsy samples (core needle or other surgical procedure) collected within 2821 days prior to Cycle 1 Day 1 (C1D1) and also on treatment unless procedure is determined to be unsafe following discussion with sponsor. Participants with an archival biopsy specimen collected within 90 days prior to C1D1 of TAK-188 who have not received any other cancer-specific treatment (with the exception of adjuvant endocrine therapy for a history of breast cancer) at least 14 days prior to the biopsy and throughout the period leading up to C1D1 may use that archival specimen in lieu of a new pretreatment biopsy. Archival biopsy from the same tumor must be provided, if available. On-treatment tumor biopsies will be optional in mainland China, but are highly desired.
  • EditedSerum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × ULN or baseline; or, for participants with liver metastases, ≤5.0 × ULN or baseline with liver metastases.
  • AddedAdequate renal function, as determined by both of the following:
  • Added<!-- -->
  • EditedCalculated creatinine clearance CLCR (using the Cockcroft-Gault formula) ≥60 mL/minute., and
  • AddedUrine protein-creatinine ratio (UPCR) of ≤0.5. (For participants with a UPCR >0.5 to <1, participant may be considered for enrollment only after discussion with the sponsor medical monitor or its designee).
  • EditedClinically significant toxic effects of previous therapy have recovered to Grade 1 (per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, and/or autoimmune endocrinopathies with stable endocrine replacement therapy.
  • Editedpancreatic ductal adenocarcinoma (PDAC). iii. Nonsquamous and squamous nonsmall cell lung cancer (NSCLC) (participants with actionable genomic alteration [AGAs] are allowed in dose escalation only).
  • EditedParticipants with metastatic or advanced solid tumors must have radiographically measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. Lesions to be used as measurable disease for the purpose of response assessment must either a) not reside in a field that has been subjected to prior radiotherapy or b) have demonstrated clear evidence of radiographic progression since the completion of prior radiotherapy and before trial enrollment or c) have been radiated at least 6 months before trial enrollment or d) should not be the same lesion selected for mandatory biopsy at screening.
  • EditedNOTE: Prior anti-PD-(L)1 therapy may have been given with or without an anti-cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody and/or chemotherapy (for example, carboplatin and pemetrexed).
  • EditedTumors must have a PD-L1 combined Positive Score (CPS) ≥1.
  • AddedFor phase 1b backfill and possible expansion in PDAC:
  • AddedParticipants with pathologically confirmed (cytological diagnosis is adequate) locally advanced or metastatic PDAC.
  • AddedMust have had disease progression in the advanced or metastatic setting. Participants must have had at least 1, and no more than 2, lines of therapy in the advanced or metastatic setting. This may have included standard of care chemotherapies and may include a RAS inhibitor or a combination of the two.
Exclusion criteria
  • EditedSystemic infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before the first dose of TAK-188 or severe infections on continued treatment.
  • EditedParticipants with uncontrolled, knownautoimmune diseases which currently require ongoing systemic therapy or suspectedhave required systemic therapy within the preceding 3 months (for example, autoimmunetraditional disease-modifying antirheumatic drugs, biologics, and so forth). Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to an autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  • EditedPrior or current clinically significant ascites, as measured by physical examination, that requires activeregularly scheduled paracentesis for control.
  • EditedAny pre-existing medical or psychiatric condition or illness, metabolic dysfunction, physical examination finding, or clinical laboratory finding that gives reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug or that would limit compliance with trial requirements or compromise ability to provide written informed consent. Participants with a history of PEpulmonary embolism on anti-coagulation are permitted unless symptomatic requiring oxygen supplementation.
Oct 14, 2026
Interventions
Arm changed Phase 2; Dose Expansion: Cohort B→Phase 2; Dose Optimization; Phase 2; Dose Expansion: Cohort C→Phase 2; Dose Expansion: Cohort B (Optional). Arms removed: Phase 2; Dose Expansion: Cohort D
Oct 14, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedPhase 1b Backfill and Phase 2 Dose Expansion and Optimization: Overall Response Rate (ORR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Up to 24 months
  • EditedPhase 1b Backfill and Phase 2 Dose Expansion and Optimization: Disease Control Rate (DCR)Time frame: Up to 24 months
  • EditedPhase 1b Backfill and Phase 2 Dose Expansion and Optimization: Duration of Response (DOR)Time frame: Up to 24 months
Oct 14, 2026
Secondary outcomes
15 edited, 7 removed
What changed in the outcomes
  • EditedPhasePhases 1 and 2: Cmax: Maximum Observed Plasma Concentration for TAK-188Time frame: Cycles 1 & 3: Day 1 (pre-dose, end of infusion, 5, 24, 48 & 72 hours post infusion); Days 8 & 15 (pre-dose); Cycles 2 & 4: Day 1 (pre-dose, end of infusion); Cycles 5,7 & 9: Day 1 (pre-dose) & at end of treatment (Cycle length:21 days) → Up to end of treatment (approximately 13 months)
  • EditedPhasePhases 1 and 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-188Time frame: Cycles 1 & 3: Day 1 (pre-dose, end of infusion, 5, 24, 48 & 72 hours post infusion); Days 8 & 15 (pre-dose); Cycles 2 & 4: Day 1 (pre-dose, end of infusion); Cycles 5,7 & 9: Day 1 (pre-dose) & at end of treatment (Cycle length:21 days) → Up to end of treatment (approximately 13 months)
  • EditedPhasePhases 1 and 2: AUC0-last: Area Under The Concentration-Time Curve From Time 0 to Time of the Last Quantifiable ConcentrationTime frame: Cycles 1 & 3: Day 1 (pre-dose, end of infusion, 5, 24, 48 & 72 hours post infusion); Days 8 & 15 (pre-dose); Cycles 2 & 4: Day 1 (pre-dose, end of infusion); Cycles 5,7 & 9: Day 1 (pre-dose) & at end of treatment (Cycle length:21 days) → Up to end of treatment (approximately 13 months)
  • EditedPhasePhases 1 and 2: AUC0-inf: Area Under The Plasma Concentration-Time Curve From Time 0 to InfinityTime frame: Cycles 1 & 3: Day 1 (pre-dose, end of infusion, 5, 24, 48 & 72 hours post infusion); Days 8 & 15 (pre-dose); Cycles 2 & 4: Day 1 (pre-dose, end of infusion); Cycles 5,7 & 9: Day 1 (pre-dose) & at end of treatment (Cycle length:21 days) → Up to end of treatment (approximately 13 months)
  • EditedPhasePhases 1 and 2: t1/2z: Terminal Disposition Phase Half-life for TAK-188Time frame: Cycles 1 & 3: Day 1 (pre-dose, end of infusion, 5, 24, 48 & 72 hours post infusion); Days 8 & 15 (pre-dose); Cycles 2 & 4: Day 1 (pre-dose, end of infusion); Cycles 5,7 & 9: Day 1 (pre-dose) & at end of treatment (Cycle length:21 days) → Up to end of treatment (approximately 13 months)
  • EditedPhasePhases 1 and 2: CL: Total Clearance After Intravenous Administration for TAK-188Time frame: Cycles 1 & 3: Day 1 (pre-dose, end of infusion, 5, 24, 48 & 72 hours post infusion); Days 8 & 15 (pre-dose); Cycles 2 & 4: Day 1 (pre-dose, end of infusion); Cycles 5,7 & 9: Day 1 (pre-dose) & at end of treatment (Cycle length:21 days) → Up to end of treatment (approximately 13 months)
  • EditedPhasePhases 1 and 2: Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-188Time frame: Cycles 1 & 3: Day 1 (pre-dose, end of infusion, 5, 24, 48 & 72 hours post infusion); Days 8 & 15 (pre-dose); Cycles 2 & 4: Day 1 (pre-dose, end of infusion); Cycles 5,7 & 9: Day 1 (pre-dose) & at end of treatment (Cycle length:21 days) → Up to end of treatment (approximately 13 months)
  • EditedPhasesPhase 1: Disease Control Rate (DCR)Time frame: Up to 24 months
  • EditedPhasesPhase 1: Duration of Response (DOR)Time frame: Up to 24 months
  • EditedPhasePhases 1 and 2: Change from Baseline in Regulatory T Cell (Treg) Abundance Within the Tumor Microenvironment (TME)Time frame: Baseline, Cycle 2 Day 10 (Cycle length: 21 Days)
  • EditedPhasePhases 1 and 2: Change from Baseline in Effector T Cell (Teff) Abundance Within the TMETime frame: Baseline, Cycle 2 Day 10 (Cycle length: 21 Days)
  • EditedPhasePhases 1 and 2: Percentage of Participants Who Develop Anti-TAK-188 AntibodiesTime frame: Cycles 1 Through 9 Day 1, and at End of Treatment (up to approximately 13 months)] → Up to the end of treatment (approximately 13 months)
  • EditedPhase 1b Backfill and Phase 2 Dose Expansion and Optimization: Time to Response (TTR)Time frame: Up to 24 months
  • EditedPhase 1b Backfill and Phase 2 Dose Expansion and Optimization: Progression-free Survival (PFS)Time frame: Up to 24 months
  • EditedPhase 1b Backfill and Phase 2 Dose Expansion and Optimization: Overall Survival (OS)Time frame: Up to 24 months
  • RemovedPhase 2: Cmax: Maximum Observed Plasma Concentration for TAK-188Time frame: Cycles 1 through 4: Days 1 and 8 (pre-dose and end of infusion); Cycles 5, 7, and 9: Day 1 (pre-dose) & at end of treatment (Cycle length: 21 Days)
  • RemovedPhase 2: Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for TAK-188Time frame: Cycles 1 through 4: Days 1 and 8 (pre-dose and end of infusion); Cycles 5, 7, and 9: Day 1 (pre-dose) & at end of treatment (Cycle length: 21 Days)
  • RemovedPhase 2: AUC0-last: Area Under The Concentration-Time Curve From Time 0 to Time of The Last Quantifiable ConcentrationTime frame: Cycles 1 through 4: Days 1 and 8 (pre-dose and end of infusion); Cycles 5, 7, and 9: Day 1 (pre-dose) & at end of treatment (Cycle length: 21 Days)
  • RemovedPhase 2: AUC0-inf: Area Under The Plasma Concentration-Time Curve From Time 0 to InfinityTime frame: Cycles 1 through 4: Days 1 and 8 (pre-dose and end of infusion); Cycles 5, 7, and 9: Day 1 (pre-dose) & at end of treatment (Cycle length: 21 Days)
  • RemovedPhase 2: t1/2z: Terminal Disposition Phase Half-life for for TAK-188Time frame: Cycles 1 through 4: Days 1 and 8 (pre-dose and end of infusion); Cycles 5, 7, and 9: Day 1 (pre-dose) & at end of treatment (Cycle length: 21 Days)
  • RemovedPhase 2: CL: Total Clearance After Intravenous Administration for TAK-188Time frame: Cycles 1 through 4: Days 1 and 8 (pre-dose and end of infusion); Cycles 5, 7, and 9: Day 1 (pre-dose) & at end of treatment (Cycle length: 21 Days)
  • RemovedPhase 2: Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-188Time frame: Cycles 1 through 4: Days 1 and 8 (pre-dose and end of infusion); Cycles 5, 7, and 9: Day 1 (pre-dose) & at end of treatment (Cycle length: 21 Days)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Enrollment 223→273
    Eligibility 9 inclusion criteria edited, 6 added; 4 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedParticipants greater than or equal to (≥)18 years or ≥ the local legal age of majority, as applicable, at the time of signing the ICFinformed consent form.
    • EditedParticipants must provide biopsy samples (core needle or other surgical procedure) collected within 2821 days prior to Cycle 1 Day 1 (C1D1) and also on treatment unless procedure is determined to be unsafe following discussion with sponsor. Participants with an archival biopsy specimen collected within 90 days prior to C1D1 of TAK-188 who have not received any other cancer-specific treatment (with the exception of adjuvant endocrine therapy for a history of breast cancer) at least 14 days prior to the biopsy and throughout the period leading up to C1D1 may use that archival specimen in lieu of a new pretreatment biopsy. Archival biopsy from the same tumor must be provided, if available. On-treatment tumor biopsies will be optional in mainland China, but are highly desired.
    • EditedSerum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × ULN or baseline; or, for participants with liver metastases, ≤5.0 × ULN or baseline with liver metastases.
    • AddedAdequate renal function, as determined by both of the following:
    • Added<!-- -->
    • EditedCalculated creatinine clearance CLCR (using the Cockcroft-Gault formula) ≥60 mL/minute., and
    • AddedUrine protein-creatinine ratio (UPCR) of ≤0.5. (For participants with a UPCR >0.5 to <1, participant may be considered for enrollment only after discussion with the sponsor medical monitor or its designee).
    • EditedClinically significant toxic effects of previous therapy have recovered to Grade 1 (per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, and/or autoimmune endocrinopathies with stable endocrine replacement therapy.
    • Editedpancreatic ductal adenocarcinoma (PDAC). iii. Nonsquamous and squamous nonsmall cell lung cancer (NSCLC) (participants with actionable genomic alteration [AGAs] are allowed in dose escalation only).
    • EditedParticipants with metastatic or advanced solid tumors must have radiographically measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. Lesions to be used as measurable disease for the purpose of response assessment must either a) not reside in a field that has been subjected to prior radiotherapy or b) have demonstrated clear evidence of radiographic progression since the completion of prior radiotherapy and before trial enrollment or c) have been radiated at least 6 months before trial enrollment or d) should not be the same lesion selected for mandatory biopsy at screening.
    • EditedNOTE: Prior anti-PD-(L)1 therapy may have been given with or without an anti-cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody and/or chemotherapy (for example, carboplatin and pemetrexed).
    • EditedTumors must have a PD-L1 combined Positive Score (CPS) ≥1.
    • AddedFor phase 1b backfill and possible expansion in PDAC:
    • AddedParticipants with pathologically confirmed (cytological diagnosis is adequate) locally advanced or metastatic PDAC.
    • AddedMust have had disease progression in the advanced or metastatic setting. Participants must have had at least 1, and no more than 2, lines of therapy in the advanced or metastatic setting. This may have included standard of care chemotherapies and may include a RAS inhibitor or a combination of the two.
    Exclusion criteria
    • EditedSystemic infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before the first dose of TAK-188 or severe infections on continued treatment.
    • EditedParticipants with uncontrolled, knownautoimmune diseases which currently require ongoing systemic therapy or suspectedhave required systemic therapy within the preceding 3 months (for example, autoimmunetraditional disease-modifying antirheumatic drugs, biologics, and so forth). Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to an autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
    • EditedPrior or current clinically significant ascites, as measured by physical examination, that requires activeregularly scheduled paracentesis for control.
    • EditedAny pre-existing medical or psychiatric condition or illness, metabolic dysfunction, physical examination finding, or clinical laboratory finding that gives reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug or that would limit compliance with trial requirements or compromise ability to provide written informed consent. Participants with a history of PEpulmonary embolism on anti-coagulation are permitted unless symptomatic requiring oxygen supplementation.
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedPhase 1b Backfill and Phase 2 Dose Expansion and Optimization: Overall Response Rate (ORR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Up to 24 months
    • EditedPhase 1b Backfill and Phase 2 Dose Expansion and Optimization: Disease Control Rate (DCR)Time frame: Up to 24 months
    • EditedPhase 1b Backfill and Phase 2 Dose Expansion and Optimization: Duration of Response (DOR)Time frame: Up to 24 months
    Secondary outcomes 15 edited, 7 removed
    What changed in the outcomes
    • EditedPhasePhases 1 and 2: Cmax: Maximum Observed Plasma Concentration for TAK-188Time frame: Cycles 1 & 3: Day 1 (pre-dose, end of infusion, 5, 24, 48 & 72 hours post infusion); Days 8 & 15 (pre-dose); Cycles 2 & 4: Day 1 (pre-dose, end of infusion); Cycles 5,7 & 9: Day 1 (pre-dose) & at end of treatment (Cycle length:21 days) → Up to end of treatment (approximately 13 months)
    • EditedPhasePhases 1 and 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-188Time frame: Cycles 1 & 3: Day 1 (pre-dose, end of infusion, 5, 24, 48 & 72 hours post infusion); Days 8 & 15 (pre-dose); Cycles 2 & 4: Day 1 (pre-dose, end of infusion); Cycles 5,7 & 9: Day 1 (pre-dose) & at end of treatment (Cycle length:21 days) → Up to end of treatment (approximately 13 months)
    • EditedPhasePhases 1 and 2: AUC0-last: Area Under The Concentration-Time Curve From Time 0 to Time of the Last Quantifiable ConcentrationTime frame: Cycles 1 & 3: Day 1 (pre-dose, end of infusion, 5, 24, 48 & 72 hours post infusion); Days 8 & 15 (pre-dose); Cycles 2 & 4: Day 1 (pre-dose, end of infusion); Cycles 5,7 & 9: Day 1 (pre-dose) & at end of treatment (Cycle length:21 days) → Up to end of treatment (approximately 13 months)
    • EditedPhasePhases 1 and 2: AUC0-inf: Area Under The Plasma Concentration-Time Curve From Time 0 to InfinityTime frame: Cycles 1 & 3: Day 1 (pre-dose, end of infusion, 5, 24, 48 & 72 hours post infusion); Days 8 & 15 (pre-dose); Cycles 2 & 4: Day 1 (pre-dose, end of infusion); Cycles 5,7 & 9: Day 1 (pre-dose) & at end of treatment (Cycle length:21 days) → Up to end of treatment (approximately 13 months)
    • EditedPhasePhases 1 and 2: t1/2z: Terminal Disposition Phase Half-life for TAK-188Time frame: Cycles 1 & 3: Day 1 (pre-dose, end of infusion, 5, 24, 48 & 72 hours post infusion); Days 8 & 15 (pre-dose); Cycles 2 & 4: Day 1 (pre-dose, end of infusion); Cycles 5,7 & 9: Day 1 (pre-dose) & at end of treatment (Cycle length:21 days) → Up to end of treatment (approximately 13 months)
    • EditedPhasePhases 1 and 2: CL: Total Clearance After Intravenous Administration for TAK-188Time frame: Cycles 1 & 3: Day 1 (pre-dose, end of infusion, 5, 24, 48 & 72 hours post infusion); Days 8 & 15 (pre-dose); Cycles 2 & 4: Day 1 (pre-dose, end of infusion); Cycles 5,7 & 9: Day 1 (pre-dose) & at end of treatment (Cycle length:21 days) → Up to end of treatment (approximately 13 months)
    • EditedPhasePhases 1 and 2: Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-188Time frame: Cycles 1 & 3: Day 1 (pre-dose, end of infusion, 5, 24, 48 & 72 hours post infusion); Days 8 & 15 (pre-dose); Cycles 2 & 4: Day 1 (pre-dose, end of infusion); Cycles 5,7 & 9: Day 1 (pre-dose) & at end of treatment (Cycle length:21 days) → Up to end of treatment (approximately 13 months)
    • EditedPhasesPhase 1: Disease Control Rate (DCR)Time frame: Up to 24 months
    • EditedPhasesPhase 1: Duration of Response (DOR)Time frame: Up to 24 months
    • EditedPhasePhases 1 and 2: Change from Baseline in Regulatory T Cell (Treg) Abundance Within the Tumor Microenvironment (TME)Time frame: Baseline, Cycle 2 Day 10 (Cycle length: 21 Days)
    • EditedPhasePhases 1 and 2: Change from Baseline in Effector T Cell (Teff) Abundance Within the TMETime frame: Baseline, Cycle 2 Day 10 (Cycle length: 21 Days)
    • EditedPhasePhases 1 and 2: Percentage of Participants Who Develop Anti-TAK-188 AntibodiesTime frame: Cycles 1 Through 9 Day 1, and at End of Treatment (up to approximately 13 months)] → Up to the end of treatment (approximately 13 months)
    • EditedPhase 1b Backfill and Phase 2 Dose Expansion and Optimization: Time to Response (TTR)Time frame: Up to 24 months
    • EditedPhase 1b Backfill and Phase 2 Dose Expansion and Optimization: Progression-free Survival (PFS)Time frame: Up to 24 months
    • EditedPhase 1b Backfill and Phase 2 Dose Expansion and Optimization: Overall Survival (OS)Time frame: Up to 24 months
    • RemovedPhase 2: Cmax: Maximum Observed Plasma Concentration for TAK-188Time frame: Cycles 1 through 4: Days 1 and 8 (pre-dose and end of infusion); Cycles 5, 7, and 9: Day 1 (pre-dose) & at end of treatment (Cycle length: 21 Days)
    • RemovedPhase 2: Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for TAK-188Time frame: Cycles 1 through 4: Days 1 and 8 (pre-dose and end of infusion); Cycles 5, 7, and 9: Day 1 (pre-dose) & at end of treatment (Cycle length: 21 Days)
    • RemovedPhase 2: AUC0-last: Area Under The Concentration-Time Curve From Time 0 to Time of The Last Quantifiable ConcentrationTime frame: Cycles 1 through 4: Days 1 and 8 (pre-dose and end of infusion); Cycles 5, 7, and 9: Day 1 (pre-dose) & at end of treatment (Cycle length: 21 Days)
    • RemovedPhase 2: AUC0-inf: Area Under The Plasma Concentration-Time Curve From Time 0 to InfinityTime frame: Cycles 1 through 4: Days 1 and 8 (pre-dose and end of infusion); Cycles 5, 7, and 9: Day 1 (pre-dose) & at end of treatment (Cycle length: 21 Days)
    • RemovedPhase 2: t1/2z: Terminal Disposition Phase Half-life for for TAK-188Time frame: Cycles 1 through 4: Days 1 and 8 (pre-dose and end of infusion); Cycles 5, 7, and 9: Day 1 (pre-dose) & at end of treatment (Cycle length: 21 Days)
    • RemovedPhase 2: CL: Total Clearance After Intravenous Administration for TAK-188Time frame: Cycles 1 through 4: Days 1 and 8 (pre-dose and end of infusion); Cycles 5, 7, and 9: Day 1 (pre-dose) & at end of treatment (Cycle length: 21 Days)
    • RemovedPhase 2: Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-188Time frame: Cycles 1 through 4: Days 1 and 8 (pre-dose and end of infusion); Cycles 5, 7, and 9: Day 1 (pre-dose) & at end of treatment (Cycle length: 21 Days)
    Interventions Arm changed Phase 2; Dose Expansion: Cohort B→Phase 2; Dose Optimization; Phase 2; Dose Expansion: Cohort C→Phase 2; Dose Expansion: Cohort B (Optional). Arms removed: Phase 2; Dose Expansion: Cohort D
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07205718
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Nov 19, 2025
Primary completion
Dec 26, 2028 (estimated)
Completion
Dec 21, 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion